Since CCND1 and FGF19 are both equally significant driver genes of the 11q13.3 amplicon in liver cancer, 11q13.3 amplification may serve as a useful biomarker for individuals who are expected to respond favorably to anti-FGF19 treatment [28]. This evidence concerns the gene FGF19 and liver cancer.